Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 9, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00408-22
Keywords
Mycobacterium tuberculosis; adverse drug effects; cytopenia; linezolid
Categories
Funding
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases [K23AI103044, R21AI122001]
- NIH Fogarty International Center [D43TW007124]
- National Center for Advancing Translational Science [UL1TR002378, TL1TR002382]
Ask authors/readers for more resources
This study investigated the long-term use of linezolid in the treatment of MDR-TB and found that cytopenias were a potential side effect. However, no interruptions in treatment were required due to cytopenias.
Although linezolid is effective for multidrug-resistant TB (MDR-TB) tuberculosis treatment, it is associated with cytopenias after 4 weeks of administration. Data on toxicities with long-term use of linezolid and drug pharmacodynamics in MDR-TB treatment are limited, and concerns about toxicity present barriers to wider implementation. This was a secondary analysis of a prospective cohort study of patients treated for MDR-TB in the country of Georgia from 2015 to 2017. Intensive blood sampling 4 to 6 weeks after treatment initiation with linezolid 600 mg daily was performed for pharmacokinetic (PK) analysis, including linezolid trough concentration (C-min) and area under the curve from 0 to 24 hours (AUC(0-24)). Linezolid exposure was defined using literature-reported thresholds. Cytopenias were defined using an NIH adverse event (AE) scale. Logistic regression was used to evaluate the relationship between linezolid exposure and cytopenias. Among 76 patients receiving linezolid in their baseline treatment regimen and who had PK data available, cytopenia AEs occurred in 30 (39.5%) for an incidence rate of 46 per 100 person-years. The median duration of linezolid therapy was 526 days. No patients required dose reduction or interruption due to cytopenias. Median linezolid C-min was 0.235 mg/L (interquartile range [IQR] 0.069 to 0.529), and median AUC(0-2)(4) was 89.6 mg.h/L (IQR, 69.2 to 116.2). Cytopenias were associated with linezolid PK parameters (C-min > 2 mg/L and AUC(0-)(24) > 160 mg.h/L). Cytopenias occurred frequently with long-term use of linezolid 600 mg/day and were associated with PK parameters but did not result in the need for treatment interruption in the management of a cohort of patients with MDR-TB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available